Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=15653663&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Current status of therapy of solid tumors: brain tumor therapy Zalutsky MRJ Nucl Med 2005[Jan]; 46 Suppl 1 (ä): 151S-6STreatment of malignant brain tumors with conventional approaches is largely unsuccessful because curative doses generally cannot be delivered without excessive toxicity to normal brain. Radioimmunotherapy is emerging as an attractive alternative for glioma therapy because of the potential for more selectively irradiating tumor cells while sparing normal tissues. Several institutions are engaged in phase I and phase II trials investigating the therapeutic potential of monoclonal antibodies (mAbs) labeled with the beta-emitters (131)I and (90)Y and the alpha-emitter (211)At in patients with recurrent and newly diagnosed brain tumors. The current status of these trials will be discussed with regard to efficacy, toxicity, and future directions.|Animals[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Brain Neoplasms/*radiotherapy[MESH]|Colonic Neoplasms/radiotherapy[MESH]|Drug Delivery Systems/*methods/*trends[MESH]|Humans[MESH]|Practice Guidelines as Topic[MESH]|Practice Patterns, Physicians'/trends[MESH]|Radioimmunotherapy/*methods/*trends[MESH]|Radioisotopes/*therapeutic use[MESH]|Radiopharmaceuticals/therapeutic use[MESH]|Treatment Outcome[MESH] |
